Nexium IV Gains Indication for GERD in Pediatric Patients

AstraZeneca announced that the FDA has approved Nexium IV (esomeprazole sodium for injection) for use in children >1 month of age for the short-term treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis when oral therapy is not possible or appropriate. Nexium IV is already indicated for use in adults ≥18 years old.

For more information call (800) 236-9933 or visit www.nexiumtouchpoints.com.